Most up-to-date research on "Biosimilars - Regulatory Framework and Pipeline Analysis" to its huge collection of research reports.
Biosimilars are copied versions of biologics that offer a 20-50% reduction in cost compared with innovative biologic products. Biosimilars are getting the world wide attention as the cost of the innovative biologics are enormously high and even minimal reduction in price will reduce the healthcare spending substantially. All the countries are focusing on reducing the healthcare expenditure and biosimilars compliments to this goal. Biologic products are complex in structure and follow a complex manufacturing process thus, some variation exists between the reference product and its biosimilar. It is very important to assess the variations in biosimilars by comparing with reference product to ensure quality, non-clinical, and clinical properties, which has given rise to the regulatory requirements for biosimilars. Regulatory requirement for approving biosimilars varies across different regulatory bodies. However, all the countries have derived the basic theme from EMA and WHO guidelines for framing their regulatory structure. There is a need to harmonize the nomenclature of biosimilars, extrapolation of indications, and interchangeability of biosimilars with reference products across the regulatory bodies. Biosimilars market is developing and it could be well established with the pipeline that is poised to deliver a wave of biosimilars in the market in the near future
Request To Download Sample Report @ http://www.researchmoz.us/enquiry.php?type=sample&repid=286559
Scope
The scope of the report includes:
Introduction
Market dynamics: Trends, Drivers, and Barriers
WHO guidance for biosimilars
Regulatory overview, biosimilar guidelines, regulatory framework for biosimilars, and market outlook for:
Europe
USA
India
South Korea
Japan
China
Key players
Pipeline Analysis
Overview
By Stage of Development / Molecule / Therapy Area / Indication
Late-Stage / Phase II / Phase I Pipeline Biosimilars
Browse Detail Report With TOC @ http://www.researchmoz.us/biosimilars-regulatory-framework-and-pipeline-analysis-report.html
Reasons To Buy
The report will enhance your decision-making capability by allowing you to:
Understand the regulatory requirement and regulatory framework that facilitates effective product development strategy as biosimilars industry is currently highly focused, growing, and outpacing the growth rate of small molecule pharmaceutical market
Targeting geographies would be easy by comparing different regulatory frameworks; this would also provide a base for designing a strategy to enter the developed markets. Biosimilars are of interest in developed countries to reduce the healthcare expenditure
With the recent approvals of biosimilars by USFDA, the biosimilars market is going to grow and this report examines the post approval market landscape
Examine the biosimilars pipeline and specifies the products that are highly targeted, it also includes analysis of highly focused indications, mechanism of actions, and therapy areas in the pipeline
Analyze the details of the clinical pipeline that includes late stage products, Phase II, and Phase I products. Detailed understanding of the pipeline will help in targeting the products for development, rate the current products and predict the competition
For Market Research Latest Reports Visit @ http://www.researchmoz.us/latest-report.html
Related Reports
Pharmaceutical Industry in China Q3 2013 - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges
This report tackles not only global pharmaceutical company interest in China but also home grown companies and their battle for position. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities. The Chinese Pharmaceutical market is currently the third greatest pharma market globally, after the US and Japan,...
Personalized Medicine and Companion Diagnostic Market Q3 2013 - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment
This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 261 tables & figures over 206 pages. The personalized medicine (global) market is presented as follows: By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen,...
Browse Our Press Releases on Prweb @ http://www.prweb.com/search.aspx?search-releases=researchmoz&x=0&y=0
0 comments:
Post a Comment